The Unraveling of Global Health Leadership

The latest polling numbers on US midterm voters’ support for Pepfar, the President’s Emergency Plan for AIDS Relief, are astonishing. Three in four likely voters back funding for this initiative, which has been a cornerstone of bipartisan foreign policy since its inception under George W Bush in 2003. This overwhelming support reveals a disconnect between Washington and American public opinion.

On one hand, the continued backing of Pepfar reflects a broader commitment to global health leadership that transcends party lines. The program’s remarkable track record in ending the HIV epidemic and building capacity for disease detection and response worldwide has earned it bipartisan recognition. Voters are more likely to support candidates who champion Pepfar, suggesting a deep-seated recognition among Americans of the moral imperative behind lifesaving treatment.

However, beneath this surface-level consensus lies a complex picture. Jennifer Kates, senior vice-president and director of global health policy at the Kaiser Family Foundation, notes that voters will see it positively if either Republicans or Democrats pursue Pepfar. This subtle distinction highlights the enduring bipartisan support for the program, which has been affected by Washington’s bureaucratic reorganization. The shift in funding from Pepfar to individual agreements with countries may seem like a technicality, but its implications are far-reaching and potentially disastrous.

The disconnect between policymakers’ priorities and public opinion is striking. Economic instability would normally drive voter concerns, yet support for Pepfar remains steadfast even against the backdrop of economic uncertainty. Polling numbers demonstrate that voters prioritize compassion and leadership on the global stage over partisan rhetoric or short-term economic considerations.

The irony is palpable when considering the Trump administration’s proposed cuts to HIV funding – $1.6 billion, mainly targeting prevention work. These measures fly in the face of overwhelming public opinion, with four in five voters recognizing the moral imperative behind lifesaving treatment. Michael Vazquez, founder and managing partner of the Maiden Group, notes that “voters do not want to feel that their vote and their tax dollars are being directed away from things that make them proud to be an American.”

The dissolution of USAID last year and its absorption into the state department has created a power vacuum, with Pepfar facing an uncertain future. Asia Russell, executive director of Health Gap, observes that “it’s like they’re cutting off the East Wing of the White House, now they want to cut off the West Wing too.” The switch to individual agreements with countries raises concerns about extractive agreements and the ability to track taxpayer dollars.

The recent Ebola outbreak in Africa serves as a stark reminder of the risks associated with neglecting global health leadership. Kates notes that “the world has made progress on ending the HIV/AIDS epidemic – but letting up the momentum now could set that progress back.” Congress must act swiftly to maintain Pepfar’s capacity and ensure continued collaboration with the CDC.

Failing to do so would be a catastrophic blow to global health leadership, with far-reaching consequences for public health worldwide. The polling numbers on Pepfar serve as a reminder that voters will not tolerate short-term gains at the expense of compassion and leadership on the global stage. As Vazquez puts it, “Americans believe really strongly in US global health leadership around the world.” It is time for policymakers to take heed of this message and prioritize the well-being of people living with or at risk of HIV/AIDS worldwide.